Literature DB >> 8825135

Use of hospital services by breast cancer patients by stage of the disease: implications on the costs of cancer control.

H Kaija1, H Matti, H Tapani.   

Abstract

The use of resources for breast cancer during the first five years after diagnosis by different stages of disease was evaluated on the basis of all breast cancer patients (555) diagnosed in the Tampere University hospital district (Finland). All outpatient visits or inpatient-days of these patients in any hospital of the district were recorded and the average costs of hospital-day and of outpatient visit were applied to quantify the total use of resources. During the first five years of follow-up 535 breast cancer patients had 8206 follow-up visits and spent 18472 days in hospital. The stage II-IV patients had more than twice as many outpatient visits and inpatient-days as the stage I patients. The number of hospital-days/patient-year was 2.4-fold for stage II patients and 4.1-fold for stage III-IV patients as compared to stage I patients. The overall use of resources/patient for those with nonlocalized disease was twice as high as the use for stage I patients, while the use of resources/person-year was 2.3-fold for stage II patients and 3.6-fold for stage III-IV as compared to stage I patients. Our study in an unselected patient population during the first five years of follow-up shows that breast cancer patients diagnosed in the early stage (stage I) require far fewer health care resources than if diagnosed in advanced stages. The results can be directly transformed into costs of breast cancer control by stage of breast cancer.

Entities:  

Mesh:

Year:  1996        PMID: 8825135     DOI: 10.1007/bf01806505

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  11 in total

1.  The cost-effectiveness of breast cancer screening.

Authors:  P J van der Maas; H J de Koning; B M van Ineveld; G J van Oortmarssen; J D Habbema; K T Lubbe; A T Geerts; H J Collette; A L Verbeek; J H Hendriks
Journal:  Int J Cancer       Date:  1989-06-15       Impact factor: 7.396

2.  Reduction of breast cancer mortality through mass screening with modern mammography. First results of the Nijmegen project, 1975-1981.

Authors:  A L Verbeek; J H Hendriks; R Holland; M Mravunac; F Sturmans; N E Day
Journal:  Lancet       Date:  1984-06-02       Impact factor: 79.321

3.  Ten- to fourteen-year effect of screening on breast cancer mortality.

Authors:  S Shapiro; W Venet; P Strax; L Venet; R Roeser
Journal:  J Natl Cancer Inst       Date:  1982-08       Impact factor: 13.506

4.  Survival of cancer patients in Finland in 1953-1974.

Authors:  T Hakulinen; E Pukkala; M Hakama; M Lehtonen; E Saxén; L Teppo
Journal:  Ann Clin Res       Date:  1981

5.  Costs of screening for breast cancer.

Authors:  M Moskowitz
Journal:  Radiol Clin North Am       Date:  1987-09       Impact factor: 2.303

Review 6.  Low-cost mass screening with mammography as a means of reducing overall mortality from breast cancer.

Authors:  R McLelland
Journal:  Radiol Clin North Am       Date:  1987-09       Impact factor: 2.303

7.  Mass screening for breast cancer: benefits, risks, costs.

Authors:  J Valentin; W Leitz
Journal:  Med Oncol Tumor Pharmacother       Date:  1988

8.  Breast cancer screening and cost-effectiveness; policy alternatives, quality of life considerations and the possible impact of uncertain factors.

Authors:  H J de Koning; B M van Ineveld; G J van Oortmarssen; J C de Haes; H J Collette; J H Hendriks; P J van der Maas
Journal:  Int J Cancer       Date:  1991-10-21       Impact factor: 7.396

9.  Reduction in mortality from breast cancer after mass screening with mammography. Randomised trial from the Breast Cancer Screening Working Group of the Swedish National Board of Health and Welfare.

Authors:  L Tabár; C J Fagerberg; A Gad; L Baldetorp; L H Holmberg; O Gröntoft; U Ljungquist; B Lundström; J C Månson; G Eklund
Journal:  Lancet       Date:  1985-04-13       Impact factor: 79.321

10.  Progress against cancer?

Authors:  J C Bailar; E M Smith
Journal:  N Engl J Med       Date:  1986-05-08       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.